Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 1/20 | 0.63 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CCND1 | P24385 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4759441 | 0.81 | BDKRB1 (0.84) | BDKRB1CYP3A4CYP2D6CYP2C9HPGD | |
| SCHEMBL4760693 | 0.80 | BDKRB1 (0.66) | BDKRB1HPGDALDH1A1SMN1; SMN2EGFR | |
| SCHEMBL5629162 | 0.77 | BDKRB1 (0.78) | BDKRB1CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1712902 | 0.77 | BDKRB1 (1.00) | BDKRB1CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4716176 | 0.77 | BDKRB1 (0.66) | BDKRB1CYP2C9ALDH1A1EGFRMEN1 | |
| SCHEMBL4716223 | 0.75 | BDKRB1 (0.67) | BDKRB1HPGDALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL4716862 | 0.75 | BDKRB1 (0.64) | BDKRB1HPGDALDH1A1SMN1; SMN2EGFR | |
| SCHEMBL4716645 | 0.75 | BDKRB1 (0.63) | BDKRB1CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4711496 | 0.74 | BDKRB1 (0.65) | BDKRB1HPGDALDH1A1SMN1; SMN2GAA | |
| SCHEMBL4716396 | 0.73 | BDKRB1 (0.61) | BDKRB1EGFRNR1H4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | claimed |
| EP-1877401-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | Elan Pharmaceuticals Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
| WO-2006113140-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | ELAN PHARMACEUTICALS, INC. (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | BDKRB1, BDKRB2, NPBWR1 | BDKRB1 1/4885P2RX7 906/4885CDK4 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.